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Clinical PerspectiveWhat Is New?Many patients with severe aortic stenosis are referred late with advanced symptoms or inappropriately denied intervention.A simple, low‐cost, facilitated data relay improves timeliness of treatment for patients diagnosed with severe aortic stenosis, resulting in a shorter time to transcatheter aortic valve replacement.What Are the Clinical Implications?Facilitated data relay has the potential to reduce perioperative and postoperative morbidity, while decreasing the number of patients dying on the waiting list for aortic valve replacement.Future studies are now needed to formally demonstrate the impact of facilitated data relay on outcome.

Introduction {#jah34441-sec-0009}
============

Aortic stenosis (AS) is a progressive, life‐threatening valve disorder that is characterized by a rapid increase in risk of sudden death once symptoms appear.[1](#jah34441-bib-0001){ref-type="ref"} Despite clear American and European guidelines on management,[2](#jah34441-bib-0002){ref-type="ref"}, [3](#jah34441-bib-0003){ref-type="ref"}, [4](#jah34441-bib-0004){ref-type="ref"}, [5](#jah34441-bib-0005){ref-type="ref"} there is evidence that gaps between current recommendations and actual clinical practice exist.[6](#jah34441-bib-0006){ref-type="ref"}, [7](#jah34441-bib-0007){ref-type="ref"}, [8](#jah34441-bib-0008){ref-type="ref"}, [9](#jah34441-bib-0009){ref-type="ref"} Patients with severe symptomatic AS may be referred late with advanced symptoms or inappropriately denied intervention.[7](#jah34441-bib-0007){ref-type="ref"}, [8](#jah34441-bib-0008){ref-type="ref"}, [10](#jah34441-bib-0010){ref-type="ref"} Patients managed in an inappropriate or untimely way incur excess morbidity and mortality, not only because of the risk of "death on the waiting list" but also from increased perioperative complications and incomplete recovery.[11](#jah34441-bib-0011){ref-type="ref"}, [12](#jah34441-bib-0012){ref-type="ref"} It is therefore important to identify ways of improving the timeliness of healthcare delivery for patients with AS.

Lack of awareness of the condition and of its consequences may represent a potentially important reason for the undertreatment observed in patients with valvular heart disease. In a recent community‐based study,[13](#jah34441-bib-0013){ref-type="ref"} although echocardiography correctly identified the disease and its severity, a significant proportion of the patients were left untreated. We then collected pilot data that replicated these findings in hospitals (secondary and tertiary care), indicating that a significant proportion of patients with symptomatic severe AS were not being referred for consideration of aortic valve intervention in a timely fashion. Simple, low‐cost facilitated data relay (FDR) interventions may help. We hypothesized that using a dedicated nurse to inform referring physicians of a finding of severe AS in a prompt and structured manner might increase the rate of referral of patients for intervention and timeliness thereof.[14](#jah34441-bib-0014){ref-type="ref"}

Methods {#jah34441-sec-0010}
=======

Study Design and Site Selection {#jah34441-sec-0011}
-------------------------------

IMPULSE was a prospective, multinational registry of patients with severe AS in Europe, the rationale and design of which has been described recently.[14](#jah34441-bib-0014){ref-type="ref"} In brief, IMPULSE evaluated the effect of a nurse‐led FDR on the timing and rate of valve procedures. A total of 23 centers from 9 countries (Austria, Czech Republic, France, Germany, Italy, The Netherlands, Spain, Switzerland, and the United Kingdom) were involved, with patients enrolled between March 2015 and April 2017. The sites were selected on the basis that each offered the full range of treatment options for AS, including surgical and transcatheter procedures, the rationale being that these might provide the best picture of service delivery. Although the 2012 guidelines applied during the conduct of the study, the results were considered against the background of the 2017 European Society of Cardiology[15](#jah34441-bib-0015){ref-type="ref"} and 2017 American College of Cardiology guidelines.[3](#jah34441-bib-0003){ref-type="ref"} The study was carried out in accordance with the Declaration of Helsinki, was approved by the independent ethics review board at each participating institution, and patient informed consent was obtained. The data that support the findings of this study are available from the corresponding author upon reasonable request.

The study had 3 phases: baseline observation phase A, to document the management of patients with severe AS enrolled during a 3‐month period; FDR intervention phase, to evaluate the efficacy of the FDR intervention among patients enrolled during the subsequent 6‐month period; and follow‐up observation phase B, to evaluate any legacy effect of the FDR intervention among patients enrolled during a final 3‐month period (Figure [1](#jah34441-fig-0001){ref-type="fig"}). During the intervention phase, the study nurse contacted the referring physician within 7 days to implement the FDR. During the 2 observation phases, there was no contact with the referring physicians. Follow‐up for all patients was capped at 3 months, when details of any treatment during the period were collected.

![Facilitated data relay. FU (follow‐up) indicates 3 months follow‐up period where effects of a potential intervention are collected and performance/nonperformance of an intervention are documented; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.](JAH3-8-e013160-g001){#jah34441-fig-0001}

Patients {#jah34441-sec-0012}
--------

Patients over 18 years of age were included in the registry based on a new finding at echocardiography of native severe AS, whether symptomatic or asymptomatic. A diagnosis of severe AS was defined as 1 or more of the following findings on echocardiography: an aortic valve area of \<1 cm^2^ (computed using a continuity equation), an indexed aortic valve area of \<0.6 cm^2^/m^2^, a maximum jet velocity of \>4 m/s, or a mean transvalvular gradient of \>40 mm Hg.[15](#jah34441-bib-0015){ref-type="ref"} Patients were excluded if they had prior aortic valve intervention.

Intervention: FDR {#jah34441-sec-0013}
-----------------

A study nurse was used at each center to monitor echocardiography results. During the first observational phase, the communication between the hospitals and referring physicians relied on usual practice in each center (eg, via a standard report or electronic discharge letter provided to the office‐based physician). This letter commonly summarizes any clinical findings, may give recommendations for further investigations but is not highlighted, may potentially not be reviewed in a timely fashion, and there may be no mechanism in place to record appropriate action.

During the intervention phase, the nurse contacted the relevant referring physician in addition to the aforementioned measures for each center and about 1 week after a patient was enrolled, to inform them that their patient had been diagnosed with severe AS on echocardiography (FDR) and had consented to participation in a study assessing follow‐up of patients with severe AS. The FDR outlined the class 1 indications for intervention in severe AS and gave all possible management options, without recommending a specific technique (transcatheter aortic valve replacement \[TAVR\] or surgical aortic valve replacement \[SAVR\]) over one another. Physicians and/or patients were contacted again 3 months later to collect details of the actual treatment given. Contact was made via a structured email, fax, or when necessary, by telephone call. A standard format was used for all communications.

Data Collection {#jah34441-sec-0014}
---------------

Data collected at baseline for all patients included demographics, medical history, and symptoms (chest pain, shortness of breath, and dizziness on exertion/syncope). Severe symptoms were defined as the presence of Canadian Cardiovascular Society class III or IV angina, New York Heart Association functional class III or IV, and/or dizziness on exertion/syncope. The logistic EuroScore I and the EuroScore II were calculated as an indication of surgical risk. Frailty was assessed according to the ability of the patient to walk 5 meters in \<6 s and to perform activities of daily living.[16](#jah34441-bib-0016){ref-type="ref"} Activities of daily living and life expectancy were assessed by the dedicated nurses or physicians, but no specific list of activities of daily living or risk calculator was recommended. The results of the echocardiographic assessment were recorded, including the presence of coexisting aortic regurgitation, mitral or tricuspid valve disease; transvalvular gradient; left ventricle dimensions; and left ventricular ejection fraction.

At 3 months after enrollment, information on vital status (alive/dead), treatment decisions (SAVR, TAVR, balloon aortic valvuloplasty \[BAV\], active decision not to treat, or watchful waiting/further diagnostics) and the number of interventions performed were documented for all patients enrolled into the study. Watchful waiting was defined as the scheduling of further patient follow‐up. Data were entered into a standardized electronic case report form by a dedicated study nurse. The primary outcome measure was the rate of planned and performed SAVR or TAVR within 3 months and the time to intervention.

Statistical Analysis {#jah34441-sec-0015}
--------------------

Data are presented descriptively, using means with SD, medians with interquartile ranges, or absolute values with percentages. Comparisons between patients enrolled during the FDR phase or observation phase B and observation phase A were made using a Pearson χ^2^ or Fisher exact test for categorical variables, and a *t* test, Mann--Whitney--Wilcoxon rank sum test, or ANOVA for continuous variables. A *P* value of \<0.05 was considered statistically significant. Statistical analysis was performed using SPSS Version 23.0 (IBM Corp., Armonk, NY).

Results {#jah34441-sec-0016}
=======

Patient Characteristics {#jah34441-sec-0017}
-----------------------

A total of 2171 patients with severe AS were enrolled (759 in observation phase A, 905 in the FDR intervention phase, and 507 in observation phase B; Figure [2](#jah34441-fig-0002){ref-type="fig"}). Of those, 1562 patients were referred by cardiologists, 273 by general physicians, 111 by cardiac surgeons, 32 by geriatricians, and 192 by other physicians (1 unknown). During the study, 44 patients were lost to follow‐up (data completeness at 3 months 98.0%) and 127 patients died (death rate 5.9%) including postoperative death. The mean age of the overall (n=2171) study population was 77.9±10.0 years, and 80% had symptomatic AS including 52% with severely limiting symptoms. Echocardiography revealed a mean aortic valve area of 0.73±0.2 cm^2^, mean indexed aortic valve area of 0.40±0.1 cm/m^2^, mean maximum jet velocity of 4.3±0.7 m/s, and mean transvalvular gradient of 47.1±14.7 mm Hg. The mean EuroScore II was 4.0±5.0%.

![Patient flow across phases. FU (follow‐up) indicates 3 months follow‐up period where effects of a potential intervention are collected and performance/nonperformance of an intervention are documented. Full FU refers to data available.](JAH3-8-e013160-g002){#jah34441-fig-0002}

Patients enrolled in the different study phases had similar demographic and disease characteristics, apart from a slightly higher proportion of patients with angina pectoris Canadian Cardiovascular Society class III/IV and severe frailty in observation phase A, and a slightly lower mean ejection fraction among patients enrolled in observation phase B (Table [1](#jah34441-tbl-0001){ref-type="table"}). Specifically, the rate of symptomatic patients and patients presenting with severe symptoms was not different across the different phases.

###### 

Patient Characteristics

                                                            Total (n=2171) Mean±SD or n/N (%)   Observation A (n=759) Mean±SD or n/N (%)   Facilitated Data Relay (n=905) Mean±SD or n/N (%)   Observation B (n=507) Mean±SD or n/N (%)   *P* Value for Comparison Across Phases
  --------------------------------------------------------- ----------------------------------- ------------------------------------------ --------------------------------------------------- ------------------------------------------ ----------------------------------------
  Age, y                                                    77.9±10.0                           77.6±10.2                                  78.0±9.5                                            78.1±10.5                                  0.520
  Female sex                                                1041/2171 (48)                      360/759 (47)                               436/905 (48)                                        245/507 (48)                               0.938
  BMI, kg/m^2^                                              27.4±5.3                            27.4±5.8                                   27.2±4.8                                            27.7±5.5                                   0.258
  Symptoms                                                                                                                                                                                                                                
  Chest pain                                                487/2076 (24)                       166/726 (23)                               201/873 (23)                                        120/477 (25)                               0.606
  Shortness of breath                                       1576/2123 (74)                      548/744 (74)                               645/888 (73)                                        383/491 (78)                               0.084
  Dizziness on exertion/syncope                             471/1941 (24)                       157/679 (23)                               210/835 (25)                                        104/427 (24)                               0.657
  NYHA class III or IV                                      859/2142 (40)                       315/755 (42)                               338/900 (38)                                        206/487 (42)                               0.120
  Angina CCS class III or IV                                91/1901 (5)                         45/676 (7)                                 29/788 (4)                                          17/437 (4)                                 0.018
  Symptomatic[a](#jah34441-note-0004){ref-type="fn"}        1743/2171 (80)                      605/759 (80)                               717/905 (79)                                        421/507 (83)                               0.199
  Severe symptoms                                           1122/2171 (52)                      402/759 (53)                               455/905 (50)                                        265/507 (52)                               0.526
  Echocardiographic valve‐related parameters                                                                                                                                                                                              
  Aortic valve area, cm^2^                                  0.73±0.2                            0.74±0.2                                   0.73±0.2                                            0.72±0.2                                   0.323
  Indexed aortic valve area, cm/m^2^                        0.40±0.1                            0.40±0.1                                   0.40±0.1                                            0.39±0.1                                   0.312
  Maximum jet velocity, m/s                                 4.3±0.7                             4.3±0.7                                    4.3±0.6                                             4.3±0.7                                    0.724
  Mean transvalvular gradient, mm Hg                        47.1±14.7                           47.2±15.0                                  47.6±14                                             46.2±14.7                                  0.237
  LVH (\>12 mm thick)                                       1324/2132 (62)                      490/758 (65)                               560/902 (62)                                        274/472 (58)                               0.068
  EF, %                                                     55.8±12                             56.0±12                                    56.5±12                                             54.4±11                                    0.008
  \>50%                                                     1492/2054 (73)                      520/720 (72)                               634/854 (74)                                        338/480 (70)                               0.245
  30--50%                                                   496/2054 (24)                       174/720 (24)                               191/854 (22)                                        131/480 (27)                               
  \<30%                                                     66/2054 (3)                         26/720 (4)                                 29/854 (3)                                          11/480 (2)                                 
  PAP, mm Hg                                                39.4±13                             39.4±13                                    40.1±13                                             38.2±13                                    0.098
  Frailty (severe)[b](#jah34441-note-0005){ref-type="fn"}   110/2141 (5)                        55/755 (7)                                 33/899 (4)                                          22/487 (5)                                 0.003
  Surgical risk                                                                                                                                                                                                                           
  Logistic EuroScore I, %                                   15.6±13.9                           15.9±13.8                                  16.3±14.5                                           14.1±12.9                                  0.157
  Logistic EuroScore II, %                                  4.0±5.0                             3.9±5.0                                    4.1±4.7                                             4.1±5.4                                    0.710

Comparisons were analyzed using Pearson χ^2^ or Fisher exact test for categorical variables, and ANOVA for continuous variables. BMI indicates body mass index; CCS, Canadian Cardiovascular Society; EF, ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; PAP, pulmonary artery pressure.

Defined as 1 or more cardiac symptoms presumably related to severe aortic stenosis (chest pain, shortness of breath, dizziness on exertion/syncope).

Defined as inability to perform 2 or more activities of daily life.

Rate and Timeliness of Intervention for AS {#jah34441-sec-0018}
------------------------------------------

During observation phase A, which was designed to demonstrate the status quo at each participating hospital before the introduction of FDR (baseline), an AVR was planned in 464/696 (67%) patients (Figure [3](#jah34441-fig-0003){ref-type="fig"}A planned; Figure [3](#jah34441-fig-0003){ref-type="fig"}B performed). Of these 464, the plan was for the majority to undergo TAVR (n=306) and fewer to undergo SAVR (n=158). Of the remaining patients identified with severe AS, 138 (20%) were considered suitable for watchful waiting, 8 (1%) were planned for balloon aortic valvuloplasty, 60 (9%) were listed as not for active treatment, and in 26 (4%), no decision was made at all. Data for the subgroup of symptomatic patients are displayed in Figure [3](#jah34441-fig-0003){ref-type="fig"}C and [3](#jah34441-fig-0003){ref-type="fig"}D. In total, 363/464 of patients (78% of the overall population) received the planned intervention within 3 months at a mean of 36±38 days in total (Figure [4](#jah34441-fig-0004){ref-type="fig"}A) and 36±37 days in symptomatic patients (Figure [4](#jah34441-fig-0004){ref-type="fig"}C).

![Proportion of AVR (total), TAVR or SAVR planned (**A**) and performed (**B**) in all patients AND planned (**C**) and performed (**D**) in symptomatic patients within 3 months during the 3 study phases. AVR indicates aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.](JAH3-8-e013160-g003){#jah34441-fig-0003}

![Time to intervention or planned date according to treatment option and study phase in patients with or without symptoms (**A** and **B**) and in symptomatic patients (**C**). FDR indicates facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.](JAH3-8-e013160-g004){#jah34441-fig-0004}

Effect of FDR {#jah34441-sec-0019}
-------------

During the intervention (FDR) phase B, there was a trend toward an increase in the number of AVRs planned compared with the observation phase, although this did not reach statistical significance (583/825, 71% versus 464/696, 67%, *P*=0.093; Figure [3](#jah34441-fig-0003){ref-type="fig"}A). There was no correlation between the timeliness of the FDR and the actual date of the intervention (Pearson *r*=0.090). There were also no differences between contact methods (phone, email/fax, or letter) for the time to intervention except for those who were referred from a physician within the hospital (*P*\<0.001). FDR did not alter the ratio of patients listed for TAVR as opposed to SAVR. However, timeliness of the intervention improved as shown by the higher number of AVR performed within 3 months (59% versus 51%, *P*=0.002; Figure [3](#jah34441-fig-0003){ref-type="fig"}B) and a significant decrease in the time to intervention by 6 days (36±38 versus 30±33 days, *P*=0.002) (Figure [4](#jah34441-fig-0004){ref-type="fig"}A). Interestingly, this effect was mainly driven by a significant improvement in timeliness of intervention in TAVR but not in SAVR (Figures [3](#jah34441-fig-0003){ref-type="fig"} and [4](#jah34441-fig-0004){ref-type="fig"}). Of interest, the effect of FDR was seen whether patients were symptomatic or not (Figure [3](#jah34441-fig-0003){ref-type="fig"}B and [3](#jah34441-fig-0003){ref-type="fig"}D).

We performed a time‐to‐event analysis for the overall AVR group as well as for those undergoing TAVI and SAVR, respectively. The time‐to‐intervention (if we consider it an event) was significantly reduced for the overall AVR analysis when the intervention phase was compared with the observational phase A with a *P=*0.002 using a log‐rank and \<0.001 using the Breslow test. This was seen when comparing observational phase B to observational phase A (*P*=0.188 and 0.257, respectively) (Figure [4](#jah34441-fig-0004){ref-type="fig"}B). If the time‐to‐event analysis is repeated for the TAVI and SAVR groups, the results reproduce the prior findings using the *t* test. While there is a significant effect of FDR on the rate of TAVI (*P*=0.011 log‐rank *P*=0.001 Breslow), there is no such effect for SAVR alone (*P*=0.066 log‐rank, *P*=0.134 Breslow). Comparisons of observational phase B to A are again not statistically significant.

FDR: A Legacy Effect? {#jah34441-sec-0020}
---------------------

Once FDR was discontinued, there was little "legacy effect." Comparing observation phase B with observation phase A, there was neither a difference in the number of AVRs planned (332/479, 69% versus 464/696, 67%) nor in the number of AVR performed within 3 months (54.9% versus 51.3%, *P*=0.223) (Table [2](#jah34441-tbl-0002){ref-type="table"} and Figure [3](#jah34441-fig-0003){ref-type="fig"}B). Overall, time to intervention was not different between phase B and phase A (34±33 versus 36±38 days, *P*=0.816) (Figure [4](#jah34441-fig-0004){ref-type="fig"}A).

###### 

Treatment Actually Performed After 3 Months

                               Observation A (n=696)   FDR (n=825)   Observation B (n=479)                
  ---------------------------- ----------------------- ------------- ----------------------- ------------ -------
  Total                                                                                                   
  AVR performed within 3 mo    357 (51.3)              487 (59.0)    0.002                   263 (54.9)   0.223
  If AVR not performed                                                                                    
  Date of AVR set              41 (5.9)                32 (3.9)      0.067                   23 (4.8)     0.419
  Date of AVR not set          66 (10)                 64 (8)        0.231                   46 (10)      0.945
  TAVR                                                                                                    
  TAVR performed within 3 mo   239 (34.3)              334 (40.5)    0.014                   173 (36.1)   0.530
  If TAVR not performed                                                                                   
  Date of TAVR set             29 (4.2)                17 (2.1)      0.017                   14 (2.9)     0.264
  No date of TAVR set          38 (5.5)                31 (3.8)      0.112                   24 (5.0)     0.735
  SAVR                                                                                                    
  SAVR performed within 3 mo   118 (17.0)              153 (19)      0.419                   90 (18.8)    0.418
  If SAVR not performed                                                                                   
  Date of SAVR set             12 (1.7)                15 (2)        0.890                   9 (1.9)      0.844
  No date of SAVR set          28 (4)                  33 (4)        0.982                   22 (4.6)     0.634

Comparisons were analyzed using Pearson χ^2^ or Fisher exact test. AVR indicates aortic valve replacement; BAV, balloon aortic valvuloplasty; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

Number of patients in whom BAV was performed within 3 months: 5/696 (0.7%) during observation phase A; 6/825 (0.7%) during intervention (facilitated data relay) phase; and 7/479 (1.5%) during observation phase B.

Facilitated Data Relay: An International Comparison {#jah34441-sec-0021}
---------------------------------------------------

Results were then investigated to determine whether there was a difference in effect of FDR between countries. Within each of the countries studied, there was an increase in the number of AVR procedures performed (Table [3](#jah34441-tbl-0003){ref-type="table"}), and, as a result, a consistent reduction in the time to intervention (Table [4](#jah34441-tbl-0004){ref-type="table"}). Within each single country, there was no significant difference in the effect of FDR, presumably because of lower power. The data from individual countries, however, together with sensitivity analysis revealed 3 important further differences. First, the percentage of cases planned ([Figure S1](#jah34441-sup-0001){ref-type="supplementary-material"}) and then actually performed ([Figure S2](#jah34441-sup-0001){ref-type="supplementary-material"}) within 3 months differs between countries, with a much higher percentage of definitive treatment delivered in a timely fashion ([Figure S3](#jah34441-sup-0001){ref-type="supplementary-material"}) within 3 months in Germany compared with the United Kingdom. Second, sequentially excluding 1 country and restricting analysis to the 4 remaining countries, much of the effect of FDR appears to be delivered by analyses that include the United Kingdom and the impact loses significance when the United Kingdom was excluded. Third, there was a strong increase in the rate of AVR performance in Italy, which further increased in the second observational phase for AVR and SAVR in particular.

###### 

Treatment Planned, and Treatment Actually Performed After 3 Months: Country‐Specific Analysis

              Total        Observation A   Facilitated Data Relay   Observation B                
  ----------- ------------ --------------- ------------------------ --------------- ------------ ---------
  Germany     n=520        n=191           n=209                                    n=120        
  AVR                                                                                            
  Planned     472 (90.8)   169 (88.5)      191 (91.4)               0.333           112 (93.3)   0.158
  Performed   449 (86.3)   164 (85.9)      181 (86.6)               0.830           104 (86.7)   0.842
  TAVR                                                                                           
  Planned     390 (75.0)   137 (71.7)      153 (73.2)               0.741           100 (83.3)   0.019
  Performed   374 (71.9)   134 (70.2)      147 (70.3)               0.969           93 (77.5)    0.156
  SAVR                                                                                           
  Planned     82 (15.8)    32 (16.8)       38 (18.2)                0.707           12 (10.0)    0.096
  Performed   75 (14.4)    30 (15.7)       34 (16.3)                0.878           11 (9.2)     0.097
  UK          n=478        n=178           n=114                                    n=186        
  AVR                                                                                            
  Planned     247 (51.7)   92 (51.7)       62 (54.4)                0.652           93 (50.0)    0.748
  Performed   135 (28.2)   48 (27.0)       42 (36.8)                0.075           45 (24.2)    0.544
  TAVR                                                                                           
  Planned     143 (29.9)   51 (28.7)       41 (36.0)                0.189           51 (27.4)    0.794
  Performed   83 (17.4)    27 (15.2)       29 (25.4)                0.030           27 (14.5)    0.861
  SAVR                                                                                           
  Planned     104 (21.8)   41 (23.0)       21 (18.4)                0.347           42 (22.6)    0.918
  Performed   52 (10.9)    21 (11.8)       13 (11.4)                0.918           18 (9.7)     0.513
  France      n=356        n=107           n=202                                    n=47         
  AVR                                                                                            
  Planned     271 (76.1)   83 (77.6)       150 (74.3)               0.520           38 (80.9)    0.648
  Performed   241 (67.7)   71 (66.4)       133 (65.8)               0.928           37 (78.7)    0.123
  TAVR                                                                                           
  Planned     150 (42.1)   42 (39.3)       83 (41.1)                0.754           25 (53.2)    0.108
  Performed   133 (37.4)   33 (30.8)       76 (37.6)                0.235           24 (51.1)    0.017
  SAVR                                                                                           
  Planned     121 (34.0)   41 (38.3)       67 (33.2)                0.366           13 (27.7)    0.202
  Performed   108 (30.3)   38 (35.5)       57 (28.2)                0.186           13 (27.7)    0.340
  Italy       n=327        n=108           n=145                                    n=74         
  AVR                                                                                            
  Planned     242 (74.0)   77 (71.3)       105 (72.4)               0.845           60 (81.1)    0.133
  Performed   198 (60.6)   51 (47.2)       91 (62.8)                0.014           56 (75.7)    \<0.001
  TAVR                                                                                           
  Planned     169 (51.7)   60 (55.6)       78 (53.8)                0.781           31 (41.9)    0.070
  Performed   133 (40.7)   38 (35.2)       68 (46.9)                0.062           27 (36.5)    0.857
  SAVR                                                                                           
  Planned     73 (22.3)    17 (15.7)       27 (18.6)                0.550           29 (39.2)    \<0.001
  Performed   65 (19.9)    13 (12.0)       23 (15.9)                0.389           29 (39.2)    \<0.001
  Others      n=319        n=112           n=155                                    n=52         
  AVR                                                                                            
  Planned     147 (46.1)   43 (38.4)       75 (48.4)                0.105           29 (55.8)    0.037
  Performed   84 (26.3)    23 (20.5)       40 (25.8)                0.317           21 (40.4)    0.008
  TAVR                                                                                           
  Planned     47 (14.7)    16 (14.3)       27 (17.4)                0.492           4 (7.7)      0.230
  Performed   23 (7.2)     7 (6.3)         14 (9.0)                 0.405           2 (3.8)      0.720
  SAVR                                                                                           
  Planned     100 (31.3)   27 (24.1)       48 (31.0)                0.218           25 (48.1)    0.002
  Performed   61 (19.1)    16 (14.3)       26 (16.8)                0.582           19 (36.5)    0.001

Comparisons were analyzed using Pearson χ^2^ or Fisher exact test. No adjustment for multiple testing was made, because the analyses are meant to explore the country‐specific effect, but with lower statistical power compared with the main analysis. AVR indicates aortic valve replacement; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

###### 

Time to Intervention: Country‐Specific Analysis

            Total       Observation A   FDR         Observation B               
  --------- ----------- --------------- ----------- --------------- ----------- ---------
  Total                                                                         
  AVR       33.0±34.7   36.45±37.6      29.9±33.0   0.002           34.0±33.0   0.816
  TAVR      29.2±34.2   35.5±39.1       24.8±31.2   \<0.001         28.4±30.5   0.182
  SAVR      40.7±34.5   38.3±34.2       40.4±34.4   0.798           44.5±35.1   0.091
  Germany                                                                       
  AVR       24.6±29.2   23.6±25.7       23.1±30.2   0.119           28.5±32.1   0.347
  TAVR      21.4±28.2   22.2±25.6       17.4±28.4   0.004           26.3±30.6   0.373
  SAVR      40.3±29.1   29.5±25.7       47.1±25.9   0.003           47.7±39.0   0.072
  UK                                                                            
  AVR       50.9±41.5   54.2±45.5       47.0±35.4   0.615           50.4±41.8   0.606
  TAVR      53.2±42.9   60.5±50.9       50.3±37.8   0.605           47.9±37.3   0.410
  SAVR      47.2±39.2   45.0±35.0       39.3±28.6   0.667           53.8±47.8   0.968
  France                                                                        
  AVR       22.0±26.2   22.2±22.1       22.9±29.5   0.242           18.3±20.0   0.209
  TAVR      20.7±25.8   23.4±20.9       21.5±29.8   0.078           14.4±15.5   0.053
  SAVR      23.6±26.7   21.2±23.3       24.7±29.3   0.965           25.5±25.4   0.672
  Italy                                                                         
  AVR       35.9±34.7   54.8±44.7       29.1±30.2   \<0.001         26.1±15.6   0.005
  TAVR      35.1±35.1   53.5±44.0       26.7±27.3   \<0.001         23.8±20.1   \<0.007
  SAVR      37.7±33.9   59.1±48.4       35.8±37.3   0.071           28.3±9.3    0.115
  Others                                                                        
  AVR       62.8±34.8   65.3±41.3       60.4±33.7   0.886           64.9±28.1   0.820
  TAVR      60.6±41.0   72.2±58.8       53.9±25.4   0.786           50.5±20.5   0.693
  SAVR      63.7±32.4   61.5±28.9       63.4±36.8   0.668           66.3±28.8   0.676

Comparisons were analyzed using Mann--Whitney *U* test. No adjustment for multiple testing was made, because the analyses are meant to explore the country‐specific effect, but with lower statistical power compared with the main analysis. AVR indicates aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

Discussion {#jah34441-sec-0022}
==========

In patients diagnosed with severe AS on echocardiography, 1 in 5 patients wait \>3 months from time of diagnosis to intervention. This delay to intervention occurred despite \>80% of patients being symptomatic, with the majority of these having severe limitations, classified as New York Heart Association or Canadian Cardiovascular Society class III or IV. Moreover, the delay to intervention occurred in hospitals in which both SAVR and TAVR were available on‐site, where one might expect intervention to occur in a timelier fashion. A simple, low cost, and easily applicable FDR intervention resulted in a greater proportion undergoing treatment within 3 months, mainly because of faster delivery of TAVR. FDR did not affect the rate of AVR. Delay to delivery of treatment differs between the countries included, with fewer receiving treatment within 3 months of a decision in the United Kingdom and a particular improvement with FDR in Italy.

Delay between the diagnosis of severe AS and an appropriate intervention is responsible for patients dying while waiting for an intervention and can increase perioperative and late complications.[11](#jah34441-bib-0011){ref-type="ref"}, [12](#jah34441-bib-0012){ref-type="ref"} Given the impact of unduly delayed intervention, the introduction of methods such as FDR that do reduce delays in management should be mandated. This is particularly important in patients with severe AS who have advanced disease at a stage when full recovery can no longer be guaranteed.[6](#jah34441-bib-0006){ref-type="ref"}, [7](#jah34441-bib-0007){ref-type="ref"}, [8](#jah34441-bib-0008){ref-type="ref"}, [17](#jah34441-bib-0017){ref-type="ref"} In the current study, 52% of patients had severely limiting symptoms and 27% had an ejection fraction of ≤50% at the time of enrollment. Since the prognosis is poor for such patients with severe AS who do not receive appropriate treatment,[18](#jah34441-bib-0018){ref-type="ref"}, [19](#jah34441-bib-0019){ref-type="ref"}, [20](#jah34441-bib-0020){ref-type="ref"} a failure to deliver outcome‐modifying treatment in 1 in 5 patients within 3 months suggests that there is an urgent need to improve quality of care. It is also noteworthy that consistently across all phases of the study, no decision was made regarding management of these high‐risk patients in 3% to 4% of cases. Given the risk of sudden cardiac death, irreversible myocardial damage, and development of congestive heart failure, which directly impact outcome, any intervention that can speed up management pathways should lead to improved outcomes, and in large populations, may reduce mortality.

There is a consensus that the best care for patients with valvular heart disease is provided by a specialist heart valve service.[21](#jah34441-bib-0021){ref-type="ref"}, [22](#jah34441-bib-0022){ref-type="ref"} One study showed that symptoms were detected earlier among patients with severe AS followed up in a structured valve clinic compared with those referred from other services, which facilitated optimized timing of surgery.[23](#jah34441-bib-0023){ref-type="ref"} Such services do not have to be physician‐led. For example, the introduction of a sonographer‐led heart valve clinic increased the proportion of patients with valvular disease managed according to best‐practice guidelines from 41% to 92%.[24](#jah34441-bib-0024){ref-type="ref"} In our study, a simple communication by a nurse resulted in faster delivery of treatment in centers that had fully capable facilities available and which one would expect should already deliver the highest quality of care. A nurse was used in the study; however, the FDR communication itself highlighted the diagnosis, the indications for intervention, and asked for options regarding management, and so could potentially be carried out automatically or by nonmedical staff. All healthcare systems are currently under financial constraint and FDR is a low‐cost intervention that was shown in this study to improve timeliness of care in AS.

There is evidence that this type of quality improvement strategy, which involves the transmission of clinical data using a means other than an existing automated system, is effective in other medical conditions.[25](#jah34441-bib-0025){ref-type="ref"} A systematic review of quality‐improvement strategies for the management of hypertension found that FDR of clinical data was associated with median reductions in systolic and diastolic blood pressure of 8.0 and 1.8 mm Hg, and a 25% increase in the proportion of patients achieving target systolic blood pressure.[26](#jah34441-bib-0026){ref-type="ref"} The results of the current study indicate that an FDR strategy can increase the rate of delivery of TAVR to patients with severe AS. A trend towards an increase in the number of surgical AS interventions being pursued was also seen during the FDR phase, although this did not achieve statistical significance. This study provides proof of concept and offers the possibility that similar benefit could be gained by automated communications containing the same information and sent to the referrer (for example, by e‐mail generated by the echocardiographer or the machine itself), to minimize delays.

The reasons for the difference in the effect of FDR on the rate of delivery of TAVR and SAVR are unknown but could possibly relate to the increased awareness of the role of TAVR in patients who are at high surgical risk or for whom surgery is contraindicated (such as very elderly patients with comorbidities). A potential explanation is that there is a fixed capacity for SAVR in a given hospital and merely adding patients to the wait list does not result in a higher throughput. On the contrary, the potential turnover of patients undergoing TAVR may be more flexible because it requires fewer resources and allows for a higher rate of AVR performance and a substantial shortening of the time to intervention. While an increase in TAVR performance capacity may contribute to this, it is unlikely to have a played a role in our setting because enrollment in each institution was limited to 3 months for observation A, 6 months for FDR, and 3 months for observation B. The fact that there are differences between countries included in this study suggest that other factors may also have an impact, which could include issues of logistics and infrastructure that appear to be much less of a problem in Germany and Italy than in the United Kingdom. All the centers involved in this study had the capability of delivering SAVR and TAVR, and it is not known whether the effect of FDR might be different in centers without direct access to these interventions. Given the adverse effect that delays can have on outcomes for patients with severe AS (as illustrated by the mortality rate of 6% within 3 months noted across each phase of the study), these results suggest that additional measures may be necessary to further reduce delays in the delivery of intervention.[27](#jah34441-bib-0027){ref-type="ref"}

There were limitations to the IMPULSE registry. As an observational, cross‐sectional study, the outcomes after valve intervention beyond 3 months were not recorded. Furthermore, although treatment decisions were documented, the actual treatment that each patient underwent may have differed. Finally, despite a total number of patients of n=2171, the study was not powered to detect a difference in outcomes such as mortality. Future study at the population level will determine whether FDR altered appropriateness of intervention. The strengths of the IMPULSE registry include its prospective design and that it is the largest prospective registry to date that documents clinical characteristics and management of contemporary patients.

Conclusions {#jah34441-sec-0023}
===========

In conclusion, a significant proportion of patients diagnosed with severe AS on echocardiography wait \>3 months from time of diagnosis to intervention. This delay to intervention occurred despite the majority being symptomatic and mostly with severe limitation. A simple, low‐cost FDR process may improve treatment pathways for patients diagnosed with severe AS, by increasing the rate of intervention performed within 3 months and decreasing the time to TAVR. Although the effect of FDR was seen, the data from this study also highlighted differences in the delivery of aortic valve intervention to patients, with many more experiencing delay in the United Kingdom compared with Germany. Although FDR did not alter the overall rate of intervention, this process could be improved and has the potential to reduce perioperative and postoperative morbidity, while decreasing the number of patients dying on the waiting list for AVR. Future studies are now needed to formally demonstrate the impact of FDR on outcome.
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**Figure S1.** Country‐specific analysis: Proportion of AVR (total), TAVR, or SAVR planned within 3 months during the 3 study phases. AVR indicates aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

**Figure S2.** Country‐specific analysis: Proportion of AVR (total), TAVR, or SAVR performed within 3 months during the 3 study phases. AVR indicates aortic valve replacement; FDR, facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

**Figure S3.** Country‐specific analysis (exclusion of countries): Time to intervention. FDR indicates facilitated data relay; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
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Click here for additional data file.

Data were captured using the s4trials Software provided by Software for Trials Europe GmbH, Berlin, Germany.
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